Skip to main
IRD
IRD logo

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc is positioned favorably due to positive topline outcomes from the Phase 3 trials for phentolamine, showcasing significant efficacy with 17.3% of patients achieving a notable improvement in visual acuity compared to 9.2% for placebo, which underscores the potential market appeal of the therapy. The upcoming supplemental New Drug Application (sNDA) submission for presbyopia is anticipated in the second half of 2025, aligning with the company's strategic development timeline and market entry objective. Additionally, the collaboration with Viatris enhances Opus's ability to effectively develop and commercialize phentolamine, thereby reinforcing its growth potential in the ophthalmic therapeutics space.

Bears say

Opus Genetics faces significant risks that impact its investment thesis and financial outlook, primarily due to the possibility of its products failing to meet peak commercial revenue estimates, which may stem from limited market size, low penetration rates, or unfavorable pricing dynamics. Additionally, the company may struggle to secure the necessary capital resources required to fund ongoing operations, thereby hindering further program development and commercialization efforts. These fundamental concerns reflect a broader uncertainty about the viability and profitability of its pipeline, which includes gene therapies and ophthalmic solutions critical for its financial success.

Opus Genetics (IRD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.